Its overexpression in uterine cervix cancer and other cancer cell types encouraged the clinical development of a pharmaceutical radioimmunoconjugate 212Pb-DOTAM-GRPR1 for the treatment of patients with metastatic or recurrent breast, prostate, colorectal, uterine cervix, melanoma, or non-small cell lung cancers overexpressing GRPR (NCT05283330). Here, GRPR is linked to cervical cancer.